Antiestrogens: the Past and the Future

References

• 1 Byers T, Mouchawar J, Marks J, Cady B, Lins N, Swanson G M,. et al . The American Cancer Society challenge goals. How far can cancer rates decline in the U.S. by the year 2015?.  Cancer. 1999;  86 715-27
• 2 Lacassagne A. Hormonal pathognesis of adenocarcinoma of the breast.  Am J Cancer. 1936;  27 217-25
• 3 Lerner L J, Holthaus JF and Thompson C R. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol.  Endocrinology. 1958;  63 295-318
• 4 Lerner L J. The first non-steroidal antioestrogen-MER 25. In: Sutherland RL, Jordan VC, editors. Nonsteroidal antioestrogens: molecular pharmacology and antitumor activity. Sydney Academic Press, Sydney 1981; 1-6
• 5 Lerner L J, Jordan V C. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.  Cancer Res. 1990;  50 4177-89
• 6 Furr B J, Jordan V C. The pharmacology and clinical uses of tamoxifen.  Pharmacol Ther. 1984;  25 127-205
• 7 Jordan V C, Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor.  Eur J Cancer. 1975;  11 205-6
• 8 MacGregor J I, Jordan V C. Basic guide to the mechanisms of antiestrogen action.  Pharmacol Rev. 1998;  50 151-96
• 9 Kedar R P, Bourne T H, Powles T J, Collins W P, Ashley S E, Cosgrove D O. et’al . Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial [see comments].  Lancet. 1994;  343 1318-21
• 10 Jordan V C, Fritz N F, Tormey D C. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.  Cancer Res. 1987;  47 4517-9
• 11 Stewart P J, Stern P H. Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro.  Endocrinology. 1986;  118 125-31
• 12 Love R R, Mazess R B, Barden H S, Epstein S, Newcomb P A, Jordan V C. et al . Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments].  N Engl J Med. 1992;  326 852-6
• 13 Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard S N, Transbol I. et al . Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.  J Clin Oncol. 1994;  12 992-7
• 14 Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen.  Atherosclerosis. 1984;  52 339-46
• 15 Love R R, Wiebe D A, Feyzi J M, Newcomb P A, Chappell R J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.  J Natl Cancer Inst. 1994;  86 1534-9
• 16 Love R R, Wiebe D A, Newcomb P A, Cameron L, Leventhal H, Jordan V C. et al . Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.  Ann Intern Med. 1991;  115 860-4
• 17 Assikis V J, Jordan V C. Gynecologic effects of tamoxifen and the association with endometrial carcinoma.  Int J Gynaecol Obstet. 1995;  49 241-57
• 18 Goldstein S R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen [see comments].  Am J Obstet Gynecol. 1994;  170 447-51
• 19 Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation.  J Clin Oncol. 1996;  14 434-40
• 20 Fisher B, Costantino J P, Wickerham D L, Redmond C K, Kavanah M, Cronin W M. et al . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst. 1998;  90 1371-88
• 21 Fisher B, Costantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 [see comments].  J Natl Cancer Inst. 1994;  86 527-37
• 22 Eifel P, Axelson J A, Costa J, Crowley J, Curran W J Jr, Deshler A. et al . National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.  J Natl Cancer Inst. 2001;  93 979-89
• 23 EBCTCG . Tamoxifen for early breast cancer: an overview of the randomised trials.  Lancet. 1998;  351 1451-67
• 24 Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M. et al . Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments].  Lancet. 1998;  352 98-101
• 25 Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C. et al . Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.  Lancet. 1998;  352 93-7
• 26 Decensi A, Bonanni B, Rotmensz N, Robertson C, Guerrieri- Gonzaga A, Mora S. et al . Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study.  Eur J Cancer. 2000;  36 Suppl. 4 50-1
• 27 Jones C D, Jevnikar M G, Pike A J, Peters M K, Black L J, Thompson A R. et al . Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3- yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.  J Med Chem. 1984;  27 1057-66
• 28 Black L J, Jones C D, Falcone J F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen.  Life Sci. 1983;  32 1031-6
• 29 Clemens J A, Bennett D R, Black L J, Jones C D. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.  Life Sci. 1983;  32 2869-75
• 30 Gottardis M M, Jordan V C. Antitumor actions of keoxifene and tamoxifen in the N- nitrosomethylurea-induced rat mammary carcinoma model.  Cancer Res. 1987;  47 4020-4
• 31 Anzano M A, Peer C W, Smith J M, Mullen L T, Shrader M W, Logsdon D L. et al . Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.  J Natl Cancer Inst. 1996;  88 123-5
• 32 Snyder K R, Sparano N, Malinowski J M. Raloxifene hydrochloride.  Am J Health Syst Pharm. 2000;  57 1669-75
• 33 Poulin R, Merand Y, Poirier D, Levesque C, Dufour J M, Labrie F. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164 384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.  Breast Cancer Res Treat. 1989;  14 65-76
• 34 Jiang S Y, Parker C J, Jordan V C. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.  Breast Cancer Res Treat. 1993;  26 139-47
• 35 Black L J, Sato M, Rowley E R, Magee D E, Bekele A, Williams D C. et al . Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.  J Clin Invest. 1994;  93 63-9
• 36 Sato M, McClintock C, Kim J, Turner C H, Bryant H U, Magee D. et al . Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.  J Bone Miner Res. 1994;  9 715-24
• 37 Turner C H, Sato M, Bryant H U. Raloxifene preserves bone strength and’bone mass in ovariectomized rats.  Endocrinology. 1994;  135 2001-5
• 38 Sato M KJ, Short L L, Slemenda C W, Bryant H U. Longitudinal and corss sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.  J Pharmacol Exp Ther. 1995;  272 1252-9
• 39 Frolik C A, Bryant H U, Black E C, Magee D E, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.  Bone. 1996;  18 621-7
• 40 Sato M, Rippy M K, Bryant H U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.  Faseb J. 1996;  10 905-12
• 41 Delmas P D, Bjarnason N H, Mitlak B H, Ravoux A C, Shah A S, Huster W J. et al . Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comments].  N Engl J Med. 1997;  337 1641-7
• 42 Ettinger B, Black D M, Mitlak B H, Knickerbocker R K, Nickelsen T, Genant H K. et al . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [see comments].  JAMA. 1999;  282 637-45
• 43 Draper M W, Flowers D E, Huster W J, Neild J A, Harper K D, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.  J Bone Miner Res. 1996;  11 835-42
• 44 Heaney R P, Draper M W. Raloxifene and estrogen: comparative bone-remodeling kinetics.  J Clin Endocrinol Metab. 1997;  82 3425-9
• 45 Bjarnason N H, Haarbo J, Byrjalsen I, Kauffman R F, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.  Circulation. 1997;  96 1964-9
• 46 Clarkson T B, Anthony M S, Jerome C P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.  J Clin Endocrinol Metab. 1998;  83 721-6
• 47 Cauley J A, Norton L, Lippman M E, Eckert S, Krueger K A, Purdie D W. et’al . Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.  Breast Cancer Res Treat. 2001;  65 125-34
• 48 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B. et al . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.  Jama. 1998;  280 605-13
• 49 Black L J, Goode R L. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice.  Life Sci. 1980;  26 1453-8
• 50 Jordan V C, Gosden B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.  Endocrinology. 1983;  113 463-8
• 51 Jordan V C, Gosden B. Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.  J Steroid Biochem. 1983;  19 1249-58
• 52 Grese T A, Cho S, Finley D R, Godfrey A G, Jones C D, Lugar W C. 3rd et al . Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.  J Med Chem. 1997;  40 146-67
• 53 Grese T A, Sluka J P, Bryant H U, Cullinan G J, Glasebrook A L, Jones C D. et al . Molecular determinants of tissue selectivity in estrogen receptor modulators.  Proc Natl Acad Sci U S A. 1997;  94 14 105-10
• 54 Boss S M, Huster W J, Neild J A, Glant M D, Eisenhut C C, Draper M W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women.  Am J Obstet Gynecol. 1997;  177 1458-64
• 55 Gottardis M M, Ricchio M E, Satyaswaroop P G, Jordan V C. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.  Cancer Res. 1990;  50 3189-92
• 56 Jordan V C, Glusman J E, Powles T J, Costa A. et al . Incident primary breast cancer are reduced by raloxifene: integrated data from multicenter, double blind, randomized trials in 12 000 postmenopausal women.  Breast Cancer Res Treat. 1998;  50
• 57 Cummings S R, Eckert S, Krueger K A, Grady D, Powles T J, Cauley J A. et’al . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [see comments].  JAMA. 1999;  281 2189-97
• 58 Green S, Walter P, Kumar V, Krust A, Bornert J M, Argos P. et al . Human oestrogen receptor cDNA: sequence, expression and homology to verb-A.  Nature. 1986;  320 134-9
• 59 Greene G L, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA.  Science. 1986;  231 1150-4
• 60 Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor.  FEBS Lett. 1996;  392 49-53
• 61 Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G. et al . Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.  J Clin Endocrinol Metab. 1997;  82 4258-65
• 62 Couse J F, Curtis S W, Washburn T F, Lindzey J, Golding T S, Lubahn D B. et’al . Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene.  Mol Endocrinol. 1995;  9 1441-54
• 63 Kumar V, Green S, Stack G, Berry M, Jin J R, Chambon P. Functional domains of the human estrogen receptor.  Cell. 1987;  51 941-51
• 64 Metzger D, Ali S, Bornert J M, Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells.  J Biol Chem. 1995;  270 9535-42
• 65 Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex.  Endocr Rev. 1996;  17 587-609
• 66 L'Horset F, Dauvois S, Heery D M, Cavailles V, Parker M G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites.  Mol Cell Biol. 1996;  16 6029-36
• 67 Kraus W L, McInerney E M, Katzenellenbogen B S. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor.  Proc Natl Acad Sci U S A. 1995;  92 12314-8
• 68 Pace P, Taylor J, Suntharalingam S, Coombes R C, Ali S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha.  J Biol Chem. 1997;  272 25832-8
• 69 Paech K, Webb P, Kuiper G G, Nilsson S, Gustafsson J, Kushner P J. et al . Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites [see comments].  Science. 1997;  277 1508-10
• 70 Shang Y, Hu X, DiRenzo J, Lazar M A, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.  Cell. 2000;  103 843-52
• 71 Catherino W H, Wolf D M, Jordan V C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.  Mol Endocrinol. 1995;  9 1053-63
• 72 Levenson A S, Catherino W H, Jordan V C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.  J Steroid Biochem Mol Biol. 1997;  60 261-8
• 73 Jiang S Y, Jordan V C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor [see comments].  J Natl Cancer Inst. 1992;  84 580-91
• 74 Brzozowski A M, Pike A C, Dauter Z, Hubbard R E, Bonn T, Engstrom O. et’al . Molecular basis of agonism and antagonism in the oestrogen receptor.  Nature. 1997;  389 753-8
• 75 Shiau A K, Barstad D, Loria P M, Cheng L, Kushner P J, Agard D A. et al . The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.  Cell. 1998;  95 927-37
• 76 Levenson A S, Jordan V C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.  Cancer Res. 1998;  58 1872-5
• 77 MacGregor Schafer J, Liu H, Bentrem D J, Zapf J W, Jordan V C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.  Cancer Res. 2000;  60 5097-105
• 78 Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.  Endocrinology. 2001;  142 838-46
• 79 Liu H, Lee E S, De los Reyes A. and al. e .Silencing and reactivation of the selective estrogen receptor modulator (SERM)-ER complex. Cancer Res 2001; 61: 3632-39
• 80 Pike A C, Brzozowski A M, Walton J, Hubbard R E, Thorsell A G, Li Y L. et al . Structural insights into the mode of action of a pure antiestrogen.  Structure (Camb). 2001;  9 145-53
• 81 Jordan V C, Koch R. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone.  Endocrinology. 1989;  124 1717-26
• 82 Gibson M K, Nemmers L A, Beckman W C Jr, Davis V L, Curtis S W, Korach K S. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue.  Endocrinology. 1991;  129 2000-10
• 83 Dauvois S, Danielian P S, White R, Parker M G. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover.  Proc Natl Acad Sci U S A. 1992;  89 4037-41
• 84 Sato M, Turner C H, Wang T, Adrian M D, Rowley E, Bryant H U. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.  J Pharmacol Exp Ther. 1998;  287 1-7
• 85 MacGregor-Schafer J, Lee E -S, Dardes R, Bentrem D, O'Regan R M, De los Reyes A. et al . Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY 353 381) and LY 117 018 in tamoxifen-stimulated breast cancer xenografts.  Clin Cancer Res. 2001;  7 2505-12
• 86 Munster P N, Buzdar A, Dhingra K, Enas N, Ni L, Major M. et al . Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.  J Clin Oncol. 2001;  19 2002-9
• 87 Ke H Z, Paralkar V M, Grasser W A, Crawford D T, Qi H, Simmons H A. et al . Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.  Endocrinology. 1998;  139 2068-76
• 88 Rosati R L, Da Silva Jardine P, Cameron K O, Thompson D D, Ke H Z, Toler S M. et al . Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336 156, a diaryltetrahydronaphthalene.  J Med Chem. 1998;  41 2928-31
• 89 Willson T M, Henke B R, Momtahen T M, Charifson P S, Batchelor K W, Lubahn D B. et al . 3-[4-(1,2-Diphenylbut-1-enyl)phenyl] acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats.  J Med Chem. 1994;  37 1550-2
• 90 Gauthier S, Caron B, Cloutier J, Dory Y L, Favre A, Larouche D. et al . (S)-(+)-4-[7-(2,2-dimethyl-1- oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.  J Med Chem. 1997;  40 2117-22
• 91 Luo S, Labrie C, Belanger A, Candas B, Labrie F. Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050).  Breast Cancer Res Treat. 1998;  49 1-11
• 92 Martel C, Labrie C, Belanger A, Gauthier S, Merand Y, Li X. et al . Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen- sensitive parameters in the ovariectomized mouse.  Endocrinology. 1998;  139 2486-92
• 93 Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice.  Cancer Res. 1998;  58 60-4
• 94 Schafer J I, Liu H, Tonetti D A, Jordan V C. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.  Cancer Res. 1999;  59 4308-13
• 95 Levenson A S, Jordan V C. Selective Oestrogen Receptor Modulation: Molecular pharmacology for the millennium.  Eur J Cancer. 1999;  35 1628-39
• 96 Pike A C, Brzozowski A M, Hubbard R E, Bonn T, Thorsell A G, Engstrom O. et al . Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.  EMBO J. 1999;  18 4608-18